Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The Perioperative Management of Subarachnoid Hemorrhage During the Coronavirus Disease 2019 Pandemic in China

Min Zeng, Shu Li, Muhan Li, Xiang Yan, Ruowen Li, Jia Dong, Yuewei Zhang, Zhongrong Miao, Shuo Wang, Yuming Peng, Ruquan Han

Key words
- Coronavirus disease 2019
- Perioperative management
- Subarachnoid hemorrhage

INTRODUCTION

The outbreak of a novel coronavirus has led to a public health emergency of international concern. Despite rigorous global containment and quarantine efforts, the total number of coronavirus disease 2019 (COVID-19) cases worldwide continues to increase. At the time of writing, the cases of COVID-19 had increased to 7,690,708, with 427,630 deaths (mortality 5.6%). In China, 83,181 cases had been confirmed, and 4634 individuals had died (mortality 5.6%).

During the ongoing COVID-19 pandemic, most hospitals have postponed or even canceled elective surgery to divert medical resources to patients with COVID-19. However, some emergent surgery is inevitable for life-threatening conditions. Subarachnoid hemorrhage (SAH) is a prevalent emergent disease of the central nervous system. Early and aggressive surgery or intervention reduces morbidity and mortality. In addition, SAH is also complicated with fever and pulmonary changes, which need to be differentiated from COVID-19. Increasingly more medical institutions outside the epicenter face the dilemma of launching routine clinical practice and preventing COVID-19. Therefore, the report of SAH cases from Beijing, China might be helpful during the pandemic.

METHODS

This report of a case series was approved by the ethics committee of Beijing Tiantan Hospital, Capital Medical University (reference number KY 2020-036-02) on May 20, 2020. Written informed consent was waived. We retrospectively observed patients with subarachnoid hemorrhage who were emergently admitted from January 23 to April 8, 2020. Based on the COVID-19 triage, patients with SAH were divided into 3 categories: positive, negative, and under investigation. During 77 days, 90 patients with SAH were admitted at the center. The median age was 55 years (range, 18–80 years) and 40 patients (44.4%) were male. None was positive, 42 patients were negative, and 48 patients were under investigation for COVID-19 before surgery. During the same period, 9 patients were diagnosed with COVID-19 without nosocomial infection.

BACKGROUND: For most of the international community outside the epicenter, coronavirus disease 2019 (COVID-19) containment is normalizing, and daily medical practice runs parallel to preventing and treating COVID-19. This experience of simultaneously conducting emergent surgery and infection control for COVID-19 disease is useful outside the epicenter during the pandemic.

CASE DESCRIPTION: In this single-center retrospective observational study, we enrolled patients with subarachnoid hemorrhage (SAH) who were emergently admitted from January 23 to April 8, 2020. Based on the COVID-19 triage, patients with SAH were divided into 3 categories: positive, negative, and under investigation. During 77 days, 90 patients with SAH were admitted at the center. The median age was 55 years (range, 18–80 years) and 40 patients (44.4%) were male. None was positive, 42 patients were negative, and 48 patients were under investigation for COVID-19 before surgery. During the same period, 9 patients were diagnosed with COVID-19 without nosocomial infection.

CONCLUSIONS: Rescuing patients with SAH and containment of COVID-19 benefit from joint prevention and control, a centralized system of equipment distribution and personnel assignment, and quick workflow establishment.
Table 1. Demographics and Baseline Information

| Variable                      | All Patients (n = 90) | Under-Investigation Group (n = 48) | Negative Group (n = 42) | P Value* |
|-------------------------------|-----------------------|------------------------------------|-------------------------|----------|
| Characteristics               |                       |                                    |                         |          |
| Age (years), median (range)   | 55 (18–80)            | 56 (18–80)                         | 55 (23–67)              | 0.411    |
| Male sex, n (%)               | 40 (44.4)             | 18 (37.5)                          | 22 (52.4)               | 0.156    |
| Body mass index (kg/m²)       | 24.0 (15.6–32.1)      | 24.0 (17.7–31.3)                   | 25.0 (15.6–32.1)        | 0.123    |
| Comorbidity, n (%)            |                       |                                    |                         |          |
| Hypertension                  | 44 (48.9)             | 24 (50.0)                          | 20 (47.6)               | 0.822    |
| Cardiovascular disease        | 10 (11.1)             | 7 (14.6)                           | 3 (7.1)                 | 0.262    |
| Respiratory disease           | 28 (31.1)             | 16 (33.3)                          | 12 (28.6)               | 0.062    |
| Endocrine system disease      | 11 (12.2)             | 7 (14.6)                           | 4 (9.5)                 | 0.465    |
| American Society of Anesthesiologists physical status | 0.453 | | | |
| III                           | 61 (67.8)             | 30 (62.5)                          | 31 (73.8)               |          |
| IV                            | 25 (27.8)             | 16 (33.3)                          | 9 (21.4)                |          |
| V                             | 4 (4.4)               | 2 (4.2)                            | 2 (4.8)                 |          |
| Hunt-Hess grade, n (%)        |                       |                                    |                         | 0.835    |
| 1                             | 25 (27.8)             | 12/48 (25.0)                       | 14/41 (33.3)            |          |
| 2                             | 52 (58.9)             | 39/48 (60.4)                       | 22/42 (52.4)            |          |
| 3                             | 7 (7.8)               | 4/48 (8.3)                         | 3/42 (7.1)              |          |
| 4                             | 6 (6.7)               | 3/48 (6.3)                         | 3/42 (7.1)              |          |
| Fisher computed tomography grade, n (%) | 0.124 | | | |
| 1                             | 22 (24.4)             | 7 (14.6)                           | 15 (35.7)               |          |
| 2                             | 38 (42.2)             | 22 (45.8)                          | 16 (38.1)               |          |
| 3                             | 15 (16.7)             | 9 (18.8)                           | 6 (14.3)                |          |
| 4                             | 15 (16.7)             | 10 (20.8)                          | 5 (11.9)                |          |
| World Federation of Neurosurgical Societies scale grade, n (%) | 0.754 | | | |
| 1                             | 56 (62.2)             | 28 (58.3)                          | 28 (66.7)               |          |
| 2                             | 11 (12.2)             | 6 (12.5)                           | 5 (11.9)                |          |
| 3                             | 5 (5.6)               | 2 (4.2)                            | 3 (7.1)                 |          |
| 4                             | 12 (13.3)             | 8 (16.7)                           | 4 (9.5)                 |          |
| 5                             | 6 (6.7)               | 4 (8.3)                            | 2 (4.8)                 |          |
| Diagnosis, n (%)              |                       |                                    |                         | 0.638    |
| Aneurysm                      | 87 (96.7)             | 46 (95.8)                          | 41 (97.6)               |          |
| Arteriovenous malformation    | 3 (3.3)               | 2 (4.2)                            | 1 (2.4)                 |          |
| Treatment, n (%)              |                       |                                    |                         | 0.265    |
| Craniotomy                    | 37 (41.1)             | 20 (41.7)                          | 17 (40.5)               |          |
| Endovascular therapy          | 39 (43.3)             | 18 (37.5)                          | 21 (50.0)               |          |
| Angiography                   | 14 (15.6)             | 10 (20.8)                          | 4 (9.5)                 |          |

*P value reflects the statistical comparison between 2 groups.
Percentage and compared by using independent tests. Nonnormally distributed variables were described as medians with interquartile range and compared by using Mann-Whitney U tests. Categorical variables were described as count and percentage and compared by using \( \chi^2 \) or Fisher exact tests. The level of significance was set at \( P < 0.05 \). Analysis was performed with SPSS version 24.0 (IBM Corp., Armonk, New York, USA).

### Table 2. Surgical and Anesthetic Information and Outcomes

| Variable                        | All Patients (n = 90) | Under-Investigation Group (n = 48) | Negative Group (n = 42) | \( P \) Value* |
|---------------------------------|----------------------|-----------------------------------|------------------------|--------------|
| Operation site, n (%)           |                      |                                   |                        | 0.254        |
| Regular OR                      | 44 (48.9)            | 24 (50.0)                         | 20 (47.6)              |              |
| Isolation OR                    | 40 (44.4)            | 19 (39.6)                         | 21 (50.0)              |              |
| Negative-pressure OR            | 6 (6.7)              | 5 (10.4)                          | 1 (2.4)                |              |
| Type of anesthesia, n (%)       |                      |                                   |                        | 0.073        |
| General anesthesia              | 72 (80.0)            | 35 (72.9)                         | 37 (88.1)              |              |
| Tracheal intubation              | 47 (52.2)            | 28 (60.0)                         | 19 (51.4)              |              |
| Laryngeal mask                  | 25 (27.8)            | 7 (20.0)                          | 18 (48.6)              |              |
| Monitored anesthesia care       | 18 (18.9)            | 13 (27.1)                         | 5 (11.9)               |              |
| Duration (minutes), mean (SD)   |                      |                                   |                        |              |
| Surgery                         | 151.6 (78.9)         | 155.9 (88.0)                      | 146.7 (67.6)           | 0.579        |
| Anesthesia                      | 192.4 (90.3)         | 196.9 (101.2)                     | 187.4 (76.8)           | 0.616        |
| Delayed tracheal extubation, n (%) | 27 (30.0)          | 15 (31.2)                         | 12 (28.6)              | 0.782        |
| Length of hospital stay (days), mean (SD) | 14.5 (10.6) | 16.2 (10.4)                      | 12.5 (10.6)            | 0.097        |
| Hospital costs (RMB \( \times 10^4 \)), mean (SD) | 127.6 (78.5)    | 129.7 (86.0)                      | 125.3 (69.9)           | 0.790        |
| Prognosis, n (%)                |                      |                                   |                        | 0.480        |
| Discharge                       | 87 (96.7)            | 47 (97.9)                         | 40 (95.2)              |              |
| Death                           | 3 (3.3)              | 1 (2.1)                           | 2 (4.8)                |              |

OR, operating room; SD, standard deviation. *\( P \) value reflects the statistical comparison between 2 groups.

### Results

During these 77 days, a total of 90 patients with SAH were consecutively admitted at the emergency. The median age was 55 years (range, 18–80 years) and 40 patients (44.4%) were male. Most patients had comorbidities, including hypertension (n = 44, 48.9%), cardiovascular disease (n = 10, 11.1%), respiratory disease (n = 28, 31.1%), and endocrine disease (n = 11, 12.2%) (Table 1).

According to the preoperative evaluation, most patients had mild to moderate SAH. Treatment involved craniotomy clipping (n = 37, 41.1%), endovascular therapy (n = 39, 43.3%), and conservative treatment after endovascular angiography (n = 14, 15.6%). The mean length of hospital stay was 14.9 days and mean cost was 127 thousand RMB. Three patients (3.3%) died and the remaining 87 were discharged from hospital (Table 2).

In the bundle of COVID-19 triage, 45 patients (50.0%) were local to Beijing and none had a history of travel to Wuhan. Abnormal preoperative results for temperature, lymphocyte count, and pulmonary presentation on chest radiography or pulmonary computed tomography were observed in 6 (6.7%), 30 (33.3%), and 26 (28.9%) patients, respectively. Based on the screening for COVID-19, none was positive, 48 patients were under investigation, and 42 had negative results. Thirty-nine patients (43.3%) completed the first pharyngeal sampling before surgery (Table 3).

The demographics, baseline characteristics, diagnosis, SAH severity and comorbidity, and surgical approach were similar between patients from the negative and under-investigation group (Table 1). More patients under investigation received surgery in a negative-pressure operating room (OR) (5 vs. 1), controlled ventilation through tracheal intubation (28 vs. 19), and delayed extubation (15 vs. 12) than did negative patients. The mean length of hospital stay was 4 days more in patients under investigation than in negative patients. During the same period, 9 patients were diagnosed with COVID-19 in the same institution without infection of health workers.

### Discussion

To contain the development of the COVID-19 pandemic, travel restrictions were imposed in Wuhan, China from January 23, 2020 to April 8, 2020. During these 77 days, 9 patients confirmed to have COVID-19, 90 patients with SAH and another 1632 patients underwent surgeries; no medical staff were infected in the center. The experience might be closely associated with the early establishment of a workflow (Figure 1) of infection control for emergent surgical patients. This workflow was created based on Chinese expert consensus for anesthesia management of surgical cases during the COVID-19 pandemic.11,13

The abnormal body temperature and white blood cell counts in patients with SAH should be differentiated from those with COVID-19. Fever is the primary sign (88.7%) of COVID-19 and a progressive
A decrease in peripheral blood lymphocyte levels was present in 83.2% of patients. Fever after SAH is common as a result of systemic inflammatory reaction, basal cistern irritation, and loss of central temperature control. Pneumonia is the most common reason for infectious fever. Lung injuries were exacerbated by increased intracranial pressure through the brain–lung cross talk mechanism.

To control the spread of COVID-19, multiple measures were imposed along with an emergent public health policy. First, comprehensive and effective preoperative evaluation and preparation were completed in a limited time frame. A standard protocol of screening was established as the COVID-19 pandemic developed and was completed on February 28, 2020, when the severe acute respiratory syndrome coronavirus 2 nucleic acid test was introduced to the screening. Two consecutive negative nucleic acid test results with intervals of 24–48 hours were required. However, only 43.3% of patients completed the first pharyngeal sampling before surgery, considering the urgency of the intervention.

Second, patients with SAH were treated in a designated area and transferred through a specific route before COVID-19 infection was clearly ruled out. After the first nucleic acid test, patients with SAH were admitted to the transition ward or directly transferred to the OR. For patients under investigation, most surgeries were performed in the negative-pressure OR and isolation OR. The negative-pressure OR and isolation OR were located at the outpatient OR and far away from the inpatient building, with isolated ventilation as well as sewage disposal systems. After surgery, patients with SAH were transferred to the isolated intensive care unit until COVID-19 was ruled out. Because of the gradual establishment of the workflow, half of the patients under investigation received surgery in the general OR at an early stage.

### Table 3. Preoperative Screening Test of COVID-19

|                                   | Under-Investigation Group (n = 48), n (%) | Negative Group (n = 42), n (%) |
|-----------------------------------|------------------------------------------|--------------------------------|
| Fever (≥37.3°C)                   | 6 (12.5)                                 | 0                              |
| Low lymphocyte count              | 30 (62.5)                                | 0                              |
| Abnormal in chest radiography     | 26 (54.2)                                | 0                              |
| History of travel to Hubei        | 0 (0.0)                                  | 0                              |
| Negative in COVID-19 nucleic acid | 17 (35.4)                                | 22 (52.4)                      |
| Abnormality in 1 item             | 33 (68.8)                                | 0                              |
| Abnormality in 2 items            | 15 (31.3)                                | 0                              |

![Figure 1](https://example.com)  
Figure 1. The workflow of the surgery procedure during the pandemic. Class III patients are those with suspected COVID-19, those with confirmed COVID-19, or those who cannot be screened. Class II patients are those in whom the possibility of COVID-19 has basically been ruled out by the emergency department or expert group but who have not completed 2 nucleic acid tests. Class I patients are those in whom the possibility of COVID-19 has basically been ruled out by the emergency department or expert group and who have completed 2 nucleic acid tests. CT, computed tomography; OR, operating room; SAH, subarachnoid hemorrhage.
Third, emergent surgical patients were generally divided into different classes according to both medical conditions and the screening test. Low-risk patients were those in whom COVID-19 was ruled out and who underwent emergency surgery in the general OR. Moderate-risk patients were those who did not complete the screening test for COVID-19 and underwent life-saving emergency surgery in the dedicated OR. High-risk patients were those with confirmed or suspected COVID-19 who received life-saving emergency surgery in the negative-pressure OR.

In the report, no patient with SAH was transferred to the designated hospital for COVID-19. Because of anesthesia practices, including endotracheal intubation, anesthesiologists have the highest risk for infection by COVID-19. Anesthesiologists were provided with level-3 protection for high-risk surgical patients.

Joint prevention and control were well embodied in our clinical practice from the beginning of the pandemic. We established a special task force to conduct the nucleic acid test for COVID-19. Physicians from the diverse departments were allocated to pharyngeal swab sampling. Researchers from the laboratory were diverted to performing the clinical nucleic acid test. The overall management was focused on prevention resources and preferentially allocated to health care staff with a high risk of infection. The prevention and control office rapidly formulated the prevention and control workflow and updated it. At the time of writing, 62 documents had been released, ensuring a safe and well-organized medical service during the pandemic.

The successful experience of treating patients with SAH and containment of COVID-19 helps to overcome this difficult period outside the epicenter and will it is hoped provide references for other national areas.

CRediT AUTHORSHIP CONTRIBUTION STATEMENT

Min Zeng: Writing - original draft. Shu Li: Methodology. Muhan Li: Visualization. Xiang Yan: Data curation. Jia Dong: Formal analysis. Yuewei Zhang: Writing - review & editing. Zhongrong Miao: Writing - review & editing. Shuo Wang: Writing - review & editing. Yuming Peng: Funding acquisition, Conceptualization. Ruquan Han: Funding acquisition, Supervision.

ACKNOWLEDGMENTS

The authors gracefully thank their colleagues in Beijing Tiantan Hospital, Capital Medical University for their support and cooperation.

REFERENCES

1. World Health Organization. Coronavirus disease (COVID-19) Situation Report—146. 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200614-covid-19-sitrep-146.pdf?sfvrsn=5088,bdad_&. Accessed June 14, 2020.
2. Lawton MT, Bates GE. Subarachnoid hemorrhage. N Engl J Med. 2017;377:257-266.
3. Mahaney KB, Todd MM, Toomer JC, HAST Investigators. Variation of patient characteristics, management, and outcome with timing of surgery for aneurysmal subarachnoid hemorrhage. J Neurosurg. 2011;114:1045-1053.
4. Obata Y, Takeda J, Sato Y, Ishikura H, Matsui T, Isotani E. A multicenter prospective cohort study of volume management after subarachnoid hemorrhage: circulatory characteristics of pulmonary edema after subarachnoid hemorrhage. J Neurosurg. 2016;125:354-363.
5. Scarselli V, Tincherro G, Citerio G. Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Fever management in SAH. Neurocrit Care. 2011;15:287-294.
6. Bowdle A, Munoz-Price LS. Preventing infection of patients and healthcare workers should be the new normal in the era of novel coronavirus epidemics. Anesthesiology. 2020;132:1292-1295.
7. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28:14-20.
8. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. J Neurosurg. 1988;68:985-986.
9. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1960;6:1-9.
10. National Health Commission and National Administrative Office of Chinese Tradition Medicine: National Recommendations for Diagnosis and Treatment of Pneumonia Caused by. 2019-nCoV. (5th edition). Available at: http://www.nhc.gov.cn/yzygj/s7532/202003d11/1442043b47d4b9bfed35d394af6f5.shtml. Accessed March 3, 2020 [in Chinese].
11. He Y, Wei J, Bian J, et al. Chinese Society of Anesthesiology Expert Consensus on Anesthetic Management of Cardiac Surgical Patients With Suspected or Confirmed Coronavirus Disease 2019. J Cardiothorac Vasc Anesth. 2020;34:1397-1401.
12. Gong Y, Cao X, Meiet W, et al. Anesthesia considerations and infection precautions for trauma and acute care cases during the COVID-19 pandemic. Anesth Analg. 2020;130:324-334.
13. Rodriguez-Moraes AI, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Truec Med Infet Dis. 2020;34:106523.
14. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
15. Frosini M, Sesti C, Valoti M, et al. Rectal temperature and prostaglandin E2 increase in cerebrospinal fluid of conscious rabbits after intracerebroventricular injection of hemoglobin. Exp Brain Res. 1999;152:351-358.
16. Mackowiak PA. Concepts of fever. Arch Intern Med. 1998;158:1870-1881.
17. Magee CA, Thompson Bastin ML, Graves K, et al. Fever burden in patients with subarachnoid hemorrhage and the increased use of antibiotics. J Stroke Cerebrovasc Dis. 2019;28:104413.
18. Mrozek S, Constantin JM, Geeraerts T. Brain-lung crosstalk: implications for neurocritical care patients. World J Crit Care Med. 2015;14:176-176.
19. Yang M, Dong H, Lu Z. Role of anesthesiologists during the COVID-19 outbreak in China. Br J Anaesth. 2020;124:666-666.
20. Chen X, Liu Y, Gong Y, et al. Perioperative management of patients infected with the novel coronavirus: recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists. Anesthesiology. 2020;132:7307-7316.

Conflict of interest statement: Funding was received from the Beijing Municipal Science and Technology Commission (21910000661906B) and Beijing Municipal Administration of Hospitals (QLT2018B02).

Received 22 June 2020; accepted 1 August 2020

Citation: World Neurosurg. (2020) 143:502-506.
https://doi.org/10.1016/j.wneu.2020.08.007

Journal homepage: www.journals.elsevier.com/world-neurosurgery

Available online: www.sciencedirect.com
### Supplementary Table 1. Subarachnoid Hemorrhage Severity Clinical Grading Scale: Hunt and Hess, World Federation of Neurosurgical Societies Scale, and Fisher Computed Tomography Scale

| Hunt and Hess Grade | World Federation of Neurosurgical Societies Scale | Fisher Computed Tomography Scale |
|---------------------|-----------------------------------------------|----------------------------------|
| 1                   | Asymptomatic or mild headache and slight nuchal rigidity | GCS score 15 | No subarachnoid hemorrhage or intraventricular hemorrhage |
|                     | Moderate to severe headache, nuchal rigidity, no focal neurologic deficit other than cranial nerve palsy | GCS score 14—13 without major focal deficit (aphasia or hemiparesis/hemiplegia) | Diffuse deposition of thin layer with all vertical layers of blood (interhemispheric fissure, insular cistern, ambient cistern) <1 mm thick |
| 3                   | Confusion, lethargy, or mild focal neurologic deficit other than cranial nerve palsy | GCS score 14—13 with major focal deficit | Vertical layers of blood ≥1 mm thick or localized clots (clots defined as >3 × 5 mm) |
| 4                   | Stupor or moderate to severe hemiparesis | GCS score 7—12 with or without major focal deficit | Diffuse or no subarachnoid blood, but with intracerebral or intraventricular clots |
| 5                   | Coma, extensor posturing, moribund appearance | GCS score 3—6 with or without major focal deficit | |

GCS, Glasgow Coma Scale.